Phapros Tbk PT (PEHA) - Total Assets

Latest as of March 2026: Rp1.43 Trillion IDR ≈ $83.80 Million USD

Based on the latest financial reports, Phapros Tbk PT (PEHA) holds total assets worth Rp1.43 Trillion IDR (≈ $83.80 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Phapros Tbk PT reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Phapros Tbk PT - Total Assets Trend (2011–2025)

This chart illustrates how Phapros Tbk PT's total assets have evolved over time, based on quarterly financial data. Explore Phapros Tbk PT (PEHA) long-term investment share to see how much of total assets are deployed in long-term investments.

Phapros Tbk PT - Asset Composition Analysis

Current Asset Composition (December 2025)

Phapros Tbk PT's total assets of Rp1.43 Trillion consist of 46.3% current assets and 53.7% non-current assets.

Asset Category Amount (IDR) % of Total Assets
Cash & Equivalents Rp70.40 Billion 8.7%
Accounts Receivable Rp350.22 Billion 25.3%
Inventory Rp153.13 Billion 11.0%
Property, Plant & Equipment Rp467.98 Billion 33.7%
Intangible Assets Rp3.81 Billion 0.3%
Goodwill Rp53.68 Billion 3.9%

Asset Composition Trend (2011–2025)

This chart illustrates how Phapros Tbk PT's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Phapros Tbk PT worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Phapros Tbk PT's current assets represent 46.3% of total assets in 2025, a decrease from 82.0% in 2011.
  • Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, up from 4.4% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2011.
  • Asset Diversification: The largest asset category is property, plant & equipment at 33.7% of total assets.

Phapros Tbk PT Competitors by Total Assets

Key competitors of Phapros Tbk PT based on total assets are shown below.

Company Country Total Assets
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.69 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
China CN¥6.49 Billion
Bausch Health Companies Inc
TO:BHC
Canada CA$24.50 Billion
Dezhan HealthCare Co Ltd
SHE:000813
China CN¥4.80 Billion
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
China CN¥8.59 Billion
Hainan Haiyao Co Ltd
SHE:000566
China CN¥5.79 Billion
Shanxi Zhendong Pharmaceutical
SHE:300158
China CN¥4.51 Billion

Phapros Tbk PT - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.10 1.24 0.95
Quick Ratio 1.65 0.90 0.62
Cash Ratio 0.00 0.00 0.00
Working Capital Rp355.71 Billion Rp132.23 Billion Rp-51.37 Billion

Phapros Tbk PT - Advanced Valuation Insights

This section examines the relationship between Phapros Tbk PT's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.60
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) -3.0%
Total Assets Rp1.39 Trillion
Market Capitalization $12.50 Million USD

Valuation Analysis

Below Book Valuation: The market values Phapros Tbk PT's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Phapros Tbk PT's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Phapros Tbk PT (2011–2025)

The table below shows the annual total assets of Phapros Tbk PT from 2011 to 2025.

Year Total Assets Change
2025-12-31 Rp1.39 Trillion
≈ $81.28 Million
-3.00%
2024-12-31 Rp1.43 Trillion
≈ $83.79 Million
-19.02%
2023-12-31 Rp1.77 Trillion
≈ $103.47 Million
-2.24%
2022-12-31 Rp1.81 Trillion
≈ $105.84 Million
-1.75%
2021-12-31 Rp1.84 Trillion
≈ $107.73 Million
-4.04%
2020-12-31 Rp1.92 Trillion
≈ $112.27 Million
-8.62%
2019-12-31 Rp2.10 Trillion
≈ $122.86 Million
+12.20%
2018-12-31 Rp1.87 Trillion
≈ $109.50 Million
+58.91%
2017-12-31 Rp1.18 Trillion
≈ $68.91 Million
+33.13%
2016-12-31 Rp883.29 Billion
≈ $51.76 Million
+29.77%
2015-12-31 Rp680.65 Billion
≈ $39.88 Million
+6.67%
2014-12-31 Rp638.09 Billion
≈ $37.39 Million
-0.78%
2013-12-31 Rp643.09 Billion
≈ $37.68 Million
+15.12%
2012-12-31 Rp558.64 Billion
≈ $32.73 Million
+20.76%
2011-12-31 Rp462.59 Billion
≈ $27.11 Million
--

About Phapros Tbk PT

JK:PEHA Indonesia Drug Manufacturers - Specialty & Generic
Market Cap
$12.50 Million
Rp213.36 Billion IDR
Market Cap Rank
#26485 Global
#582 in Indonesia
Share Price
Rp254.00
Change (1 day)
-2.31%
52-Week Range
Rp214.00 - Rp384.00
All Time High
Rp2996.89
About

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more